IN THE CLAIMS

Please cancel claims 4, 6, 14, 25-52, 58 and 60 without prejudice, and amend claims 1, 2, 5, 11, 17, 19, 21, 59 and 61, as follows:

1. (CURRENTLY AMENDED) A pharmaceutical composition, which is liquid, comprising:

agent i) selected from the group consisting of ~~an insulin,~~ an insulin analog that binds an insulin receptor and lowers blood glucose and that differs from a naturally occurring insulin by one or more amino acid differences, ~~a physiologically active fragment of said insulin~~ and a physiologically active fragment of said insulin analog,

agent ii) selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and

agent iii) an insulin sensitizer; and

a pharmaceutically acceptable non-ionic surfactant, wherein the non-ionic surfactant is a block copolymer of propylene oxide and ethylene oxide, and is present in an amount affording a concentration less than the critical micellar concentration of said composition;

wherein the insulin-related peptide is selected from the group consisting of C-peptide, glucagon-like peptide-1 (GLP-1), amylin, insulin-like growth factor-1 (IGF-1) and IGF-1 bound to binding protein 3.

2. (CURRENTLY AMENDED) The composition of claim 1 ~~wherein said agent i) is~~ , further comprising an insulin.

3. (ORIGINAL) The composition of claim 2 wherein said insulin is selected from the group consisting of human insulin, porcine insulin and bovine insulin.

4. (CANCELLED)

5. (CURRENTLY AMENDED) The composition of ~~claim 4~~ claim 1 wherein said insulin analog is selected from the group consisting of Lys^{B28} insulin, Pro^{B29} insulin and Asp^{B28} insulin.

6-7. (CANCELLED)

8. (ORIGINAL) The composition of claim 1 wherein said agent iii) is an insulin sensitizer of the glitazone family.

9. (ORIGINAL) The composition of claim 1 which is stabilized for administration by a medication infusion pump.

10. (CANCELLED)

11. (CURRENTLY AMENDED) The composition of claim 1, which ~~is a liquid and~~ comprises about 1.5 to about 40 mg/ml of agent i) and about 1.5 to about 40 mg/ml of agent ii).

12-16. (CANCELLED)

17. (CURRENTLY AMENDED) The composition of claim 1, which ~~is a liquid and~~ comprises about 0.5 to about 40 mg/ml of agent i) and about 0.05 to about 12 mg/ml of agent iii).

18. (CANCELLED)

19. (CURRENTLY AMENDED) The composition of claim 1, which ~~is a liquid and~~ comprises about 0.05 to about 12.5 mg/ml of agent ii) and about 0.05 to about 12.5 mg/ml of agent iii).

20. (PREVIOUSLY PRESENTED) The composition of claim 1 further comprising one or more additional compounds of agent i), of agent ii), or of agent iii).

21. (CURRENTLY AMENDED) A pharmaceutical composition comprising

i) at least one agent selected from the group consisting of an insulin, an insulin analog, a physiologically active insulin fragment and a physiologically active insulin analog fragment and

ii) at least one agent selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulated-related peptide analog fragment, and

iii) an insulin sensitizer; and

iv) optionally, a pharmaceutically acceptable carrier;

wherein said agent ii) comprises a hydrophobic portion that is coated with a pharmaceutically acceptable non-ionic surfactant that is a block copolymer of propylene oxide and ethylene oxide;

wherein the composition is stabilized for administration by a medication infusion pump.

22-58. (CANCELLED)

59. (CURRENTLY AMENDED) A pharmaceutical composition comprising agents i) - iii), wherein

agent i) is selected from the group consisting of ~~an~~ a small molecule insulin mimetic material,

agent ii) is selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment, and a physiolgically active insulin-related peptide analog fragment, and

agent iii) is an insulin sensitizer;

wherein the insulin-related peptide is selected from the group consisting of C-peptide, glucagon-like peptide-1 (GLP-1), amylin, insulin-like growth factor-1 (IGF-1) and IGF-1 bound to binding protein 3; and

wherein agents i) and ii) are combined with a pharmaceutically acceptable non-ionic surfactant that is a block copolymer of propylene oxide and ethylene oxide.

60. (CANCELLED)

61. (CURRENTLY AMENDED) The composition of claim 60 wherein the small molecule insulin mimetic material is L-783,281, having the structure:



62. (ORIGINAL) The composition of claim 59 wherein said agent ii) is an insulin-related peptide.

63. (CANCELLED)

64. (ORIGINAL) The composition of claim 59 wherein said agent iii) is an insulin sensitizer of the glitazone family.

65. (ORIGINAL) The composition of claim 59 which is stabilized for administration by a medication infusion pump.

66. (PREVIOUSLY PRESENTED) The composition of claim 59, which is a liquid and comprises about 1.5 to about 40 mg/ml of agent i), about 1.5 to about 40 mg/ml of agent ii), and about 0.05 to about 12.5 mg/ml of agent iii).

67-70. (CANCELLED)

71. (PREVIOUSLY PRESENTED) The composition of claim 59 further comprising one or more additional compounds of agent i), of agent ii), or of agent iii).